NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Paras Petrofils Reports FY26 Net Loss of ₹35.37 Lacs; Zero Revenue from Operations
Paras Petrofils Limited reported a net loss of ₹35.37 Lacs for the financial year ended March 31, 2026, a sharp decline from a profit of ₹7.82 Lacs in the previous fiscal year. The company recorded zero revenue from operations for the entire year, with its total income of ₹149.82 Lacs coming entirely from 'Other Income'. For the quarter ended March 31, 2026, the net loss widened to ₹128.51 Lacs compared to a loss of ₹79.67 Lacs in the corresponding quarter of the previous year.
முக்கிய அம்சங்கள்
Reported zero revenue from operations for both Q4 FY26 and the full financial year 2025-26.Annual net loss of ₹35.37 Lacs in FY26 compared to a net profit of ₹7.82 Lacs in FY25.Q4 FY26 net loss widened to ₹128.51 Lacs from ₹79.67 Lacs in Q4 FY25.Total expenses for FY26 increased to ₹185.19 Lacs, primarily driven by 'Other Expenses' of ₹183.27 Lacs.Earnings Per Share (EPS) for FY26 stood at negative ₹0.01.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as the company lacks core business operations and is currently loss-making. The reliance on non-operational income and the absence of revenue streams indicate significant fundamental weakness.
NCLAT Upholds Insolvency Proceedings Against Parsvnath Developers for ₹3,942 Crore Default
The National Company Law Appellate Tribunal (NCLAT) has upheld the National Company Law Tribunal's (NCLT) decision to initiate the Corporate Insolvency Resolution Process (CIRP) against Parsvnath Developers Limited. The proceedings were initiated by Asset Reconstruction Company (India) Ltd (ARCIL) following a default of approximately ₹3,942.27 crore. Despite the company's claims of having paid ₹200 crore and being in settlement talks for a ₹750 crore repayment plan, the court confirmed the existence of debt and default. Consequently, the company is now under a moratorium, and an Interim Resolution Professional (IRP) has taken control of the management.
முக்கிய அம்சங்கள்
NCLAT upheld the NCLT order dated April 30, 2026, admitting Parsvnath Developers into CIRP under Section 7 of the IBC.The default amount claimed by the financial creditor (ARCIL) stands at ₹3,942,26,92,456.The insolvency process also applies to Noida Marketing Private Limited, which acted as a corporate guarantor for the loans.The court noted that while settlement talks occurred, no final formal agreement was executed to stay the insolvency proceedings.A moratorium has been declared, and an Interim Resolution Professional (IRP) has been appointed to manage the company's affairs.
👀 கவனிக்க வேண்டியவை
Investors should be extremely cautious as the company has entered CIRP, which typically results in significant equity dilution or total loss for shareholders. It is advisable to monitor the resolution professional's updates and the progress of the insolvency process closely.
BIL Vyapar Reports FY26 Results Under CIRP; Auditors Issue Disclaimer of Opinion
BIL Vyapar Limited (formerly Binani Industries) has released its FY26 financial results while undergoing Corporate Insolvency Resolution Process (CIRP). The statutory auditors have issued a Disclaimer of Opinion, stating they could not obtain sufficient evidence to provide a basis for an audit opinion. The company's net worth is completely eroded with accumulated losses of INR 21,766.17 lakhs, and current liabilities exceed current assets by INR 18,627.68 lakhs. Consequently, the financial statements have been prepared on a liquidation basis rather than as a going concern.
முக்கிய அம்சங்கள்
Auditors issued a Disclaimer of Opinion for FY26 due to lack of evidence on asset valuations and liabilities.Accumulated losses reached INR 21,766.17 lakhs, resulting in total erosion of net worth.Current liabilities exceed current assets by INR 18,627.68 lakhs as of March 31, 2026.Financials are prepared on a liquidation basis as the 'going concern' assumption is no longer valid.Outstanding corporate guarantees of INR 8,025 lakhs for Edayar Zinc Limited remain a significant admitted claim.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as the company is in insolvency proceedings and the auditors cannot verify the financial statements. The preparation of accounts on a liquidation basis indicates a high risk that equity shareholders may receive little to no value during the resolution process.
Sai Parenterals FY26 Revenue Jumps 133% to ₹381 Cr; Targets ₹750 Cr Revenue in FY27
Sai Parenterals reported a transformational FY26 with consolidated revenue growing 133% to ₹381 crore, significantly boosted by the acquisition of Australia-based Noumed Pharmaceuticals. The company is currently executing a ₹440 crore growth capex program, including EU-GMP upgrades in India and a new facility in Adelaide, Australia. Management has issued strong guidance for FY27, targeting ₹750 crore in revenue and 17% EBITDA margins, with FY28 expected to show the full impact of current investments. The integration of Noumed provides access to 451 IP dossiers and major Australian pharmacy networks.
முக்கிய அம்சங்கள்
Consolidated FY26 revenue reached ₹381 crore, up 133% YoY, while standalone PAT grew 64% to ₹17 crore.Management guidance for FY27 targets ₹750 crore revenue and 17% EBITDA margins.Executing a ₹440 crore capex program, including ₹111 crore for India upgrades and ₹311 crore for the Adelaide facility.Acquisition of Noumed Pharmaceuticals adds 451 IP dossiers and distribution access to 2,100 pharmacies in Australia.Vertical integration benefits and internalization of Noumed's manufacturing are expected to drive significant margin expansion in FY28.
👀 கவனிக்க வேண்டியவை
Investors should track the timely commissioning of the Adelaide facility and EU-GMP upgrades in India by Q4 FY27, as these are the primary catalysts for the projected doubling of revenue. The successful integration of Noumed's IP portfolio into the Indian manufacturing base remains a key monitorable for margin improvement.
Apeejay Surrendra Park Hotels Limited (ASPHL) reported a 12% YoY growth in FY26 revenue to ₹7,073 million, driven by industry-leading occupancy of 91%. Despite the revenue growth, annual PAT declined by 21.4% to ₹657 million, with EBITDA margins contracting by 218 bps to 30.82%. The company's retail F&B brand, Flurys, delivered a robust 29% revenue growth, while the company maintained a strong balance sheet with a Net Debt to Equity ratio of 0.12x.
முக்கிய அம்சங்கள்
Annual Revenue grew 12% YoY to ₹7,073 Mn, crossing the ₹700 Cr milestone for the first time.Maintained industry-leading occupancy levels at 91% with an Average Room Rate (ARR) of ₹8,304 for FY26.Flurys revenue increased by 29% YoY to ₹829 Mn, expanding its footprint to 110 outlets across India.Aggressive expansion roadmap targets doubling the portfolio to 85 hotels and 6,635 keys by FY30.Board approved a 75% dividend payout, reflecting confidence in the company's cash flow and balance sheet.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's ability to recover margins as it transitions toward a more asset-light managed model. The long-term growth story remains intact given the aggressive FY30 expansion targets and strong performance in the F&B segment.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Sai Parenterals Bags 10-Year Order Worth Rs 104.50 Cr from PILL CORP, Philippines
Sai Parenterals Limited has secured a significant international contract from PILL CORP, Philippines, for the supply of anti-TB products. The contract is valued at USD 11 million, which translates to approximately Rs. 104.50 Crores at an exchange rate of Rs. 95 per USD. This is a long-term agreement spanning 10 years on an exclusivity basis, starting from June 1, 2026. The deal provides long-term revenue visibility and strengthens the company's footprint in the international pharmaceutical market.
முக்கிய அம்சங்கள்
Total contract value of USD 11 million (approximately Rs. 104.50 Crores).10-year exclusive supply agreement for anti-TB products in the Philippines market.Contract execution is set to commence on June 1, 2026.Valuation calculated at a fixed exchange rate of Rs. 95 per USD.The order is from an international entity with no promoter group interest or related party involvement.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development for long-term revenue stability; however, they should monitor the execution of periodic purchase orders and the impact of currency fluctuations on margins.
BIL Vyapar CoC Approves ₹4.59 Lakh Expenses and Appoints Valuers in 11th Meeting
BIL Vyapar Limited, currently undergoing Corporate Insolvency Resolution Process (CIRP), has disclosed the minutes of its 11th Committee of Creditors (CoC) meeting. The CoC ratified operational expenses totaling ₹4,59,155.98 and approved the appointment of two coordinating valuation entities. These appointments, including R&A Valuation and G N Fair Valuation at fees of ₹60,000 each, are critical steps in determining the company's asset value for the resolution process.
முக்கிய அம்சங்கள்
Ratified insolvency-related expenses amounting to ₹4,59,155.98.Appointed R&A Valuation entity as a Co-ordinating Valuer for a fee of ₹60,000 plus taxes.Approved G N Fair Valuation Pvt Ltd as a second Co-ordinating Valuer for a fee of ₹60,000 plus taxes.Ratified the appointment and professional fees for Namawala Associates in the CIRP matter.
👀 கவனிக்க வேண்டியவை
Investors should remain cautious as the company is under CIRP, which typically involves high risk for equity holders; monitor future disclosures regarding the final resolution plan and recovery values.
Paramount Communications FY26 Revenue Up 23% to ₹1,912 Cr; Q4 PAT Surges 175% QoQ
Paramount Communications reported a resilient FY26 with revenue growing 23% YoY to ₹1,912 crore, despite significant margin pressure from US tariff hikes earlier in the year. Q4 FY26 showed a strong sequential recovery with PAT rising 175% QoQ to ₹20.5 crore as EBITDA margins improved to 6.7%. The company successfully pivoted to the domestic market, which grew 27% to ₹1,361 crore, while the invalidation of US tariffs by the Supreme Court in early 2026 positions the export segment for a strong FY27 recovery.
முக்கிய அம்சங்கள்
FY26 Revenue reached ₹1,912 crore, representing a 4-year CAGR of 35.4%.Q4 FY26 EBITDA margins recovered to 6.7% from 4.3% in Q3 FY26, a 240 bps sequential improvement.Domestic order book stands at ₹508 crore, comprising 87% of the total ₹583 crore backlog as of March 31, 2026.US export competitiveness restored following Supreme Court rulings invalidating tariffs that had reached up to 50%.Metal throughput increased by 12% YoY to over 29,500 metric tons across existing plants.
👀 கவனிக்க வேண்டியவை
Investors should focus on the expected margin expansion in FY27 as high-margin US exports resume without tariff burdens. The company's strong domestic positioning in power and infrastructure makes it a key beneficiary of India's ongoing Capex cycle.
Parsvnath Developers Delays FY26 Financial Results Due to Ongoing Insolvency Process
Parsvnath Developers Limited has informed the stock exchanges of a delay in submitting its standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company is currently undergoing the Corporate Insolvency Resolution Process (CIRP), which has complicated the timely finalization of accounts. While the company claims to endeavor to ensure compliance, it cited unavoidable circumstances for missing the statutory deadline. This delay reflects the ongoing financial and administrative distress at the company.
முக்கிய அம்சங்கள்
Delay in submission of Standalone and Consolidated financial results for the quarter and year ended March 31, 2026.Company is currently under the Corporate Insolvency Resolution Process (CIRP).Non-compliance with SEBI (LODR) Regulation 33 regarding the 60-day timeline for annual results.Cited 'unavoidable circumstances' as the primary reason for the reporting failure.
👀 கவனிக்க வேண்டியவை
Investors should remain extremely cautious as the company is in insolvency proceedings and failing to meet basic regulatory reporting requirements. Equity holders typically face significant risk of total loss or extreme dilution during the CIRP resolution.
Apar Industries Reports FY26 Revenue of ₹22,902 Cr with 29% 5-Year CAGR
Apar Industries has released its May 2026 corporate presentation, highlighting a strong financial performance with FY26 revenue reaching ₹22,902 crore. The company maintains its global leadership as the world's largest aluminium conductor manufacturer and the 3rd largest transformer oil producer. The conductor segment remains a major growth engine, contributing ₹12,712 crore to the top line with a 34.2% 5-year CAGR. Exports continue to be a strategic pillar, accounting for 29.9% of total revenue and reaching over 140 countries.
முக்கிய அம்சங்கள்
FY26 consolidated revenue reached ₹22,902 crore ($2.54 billion) with a 29% 5-year CAGR.Conductor segment revenue stood at ₹12,712 crore, with premium products like HTLS and AL59 contributing 46%.Export revenue contributed 29.9% to the total FY26 revenue, supported by 11 global manufacturing plants.Maintains #1 global position in aluminium conductors and #3 global position in transformer oils.Successfully raised ₹1,000 crore through a QIP in 2024 to fund greenfield expansions in the cables segment.
👀 கவனிக்க வேண்டியவை
Investors should monitor the increasing share of high-margin premium products in the conductor segment and the company's expansion into EV wiring and renewable energy cables. The stock remains a key beneficiary of global energy infrastructure spending and the 'China Plus One' strategy in manufacturing.
Apar Industries Q4 FY26 Revenue Up 26.7% to ₹6,603 Cr; FY26 Revenue Hits All-Time High
Apar Industries reported a strong performance for FY26, with annual revenue reaching an all-time high of ₹22,902 crores, a 23.3% increase YoY. Q4 FY26 revenue grew 26.7% to ₹6,603 crores, driven by robust domestic demand and scaling of the US business. While Q4 PAT grew only 1.4% to ₹254 crores due to one-off expenses related to the new wage code and legal provisions, the underlying PAT growth excluding these items was 14%. The Conductor and Cable divisions showed strong momentum with revenue growth of 29.9% and 35.0% respectively in Q4.
முக்கிய அம்சங்கள்
Consolidated FY26 revenue reached a record ₹22,902 crores, up 23.3% YoYQ4 EBITDA grew 19.3% YoY to ₹584 crores, with an EBITDA margin of 8.8%Conductor division order book stands at ₹7,671 crores with a 24.2% increase in FY26 order inflowsCable division revenue surged 35% YoY in Q4, supported by a 52.2% growth in US revenuesAdjusted for one-off expenses, FY26 PAT would have grown by 27% compared to the reported 19%
👀 கவனிக்க வேண்டியவை
Investors should focus on the strong volume growth in Conductors and Cables and the record-high order book. The one-off impacts in Q4 are non-recurring, making the underlying business performance look healthy for long-term growth.
Apar Industries FY26 PAT Rises 19% to ₹977 Cr; Recommends ₹60 Dividend
Apar Industries reported a strong performance for the financial year ended March 31, 2026, with consolidated revenue growing 23% YoY to ₹22,902 crore. Net profit for the full year increased by 19% to ₹977 crore, even after accounting for a ₹32.5 crore exceptional charge related to employee benefits. The company's Board has recommended a substantial final dividend of ₹60 per share, reflecting strong cash flows. Segment growth was led by the Conductors and Cables divisions, which saw significant revenue jumps compared to the previous year.
முக்கிய அம்சங்கள்
Consolidated Revenue for FY26 grew 23.2% YoY to ₹22,902.12 crore.Full-year Net Profit (PAT) increased 18.9% to ₹976.93 crore from ₹821.30 crore.Recommended a final dividend of ₹60 per equity share (600% of face value).Conductor segment revenue jumped 32.6% YoY to ₹12,711.95 crore.Approved further investment of up to BRL 550,000 in the Brazilian wholly-owned subsidiary.
👀 கவனிக்க வேண்டியவை
Investors should take note of the robust top-line growth and the high dividend payout as signs of operational strength. The company's continued expansion in international markets like Brazil and the appointment of Tier-1 auditors suggest a positive outlook on growth and governance.
Apeejay Surrendra Park Hotels Recommends Final Dividend of ₹0.75 per Share for FY26
The Board of Directors of Apeejay Surrendra Park Hotels has recommended a final dividend of ₹0.75 per equity share of face value ₹1 for the financial year ended March 31, 2026. This recommendation is subject to shareholder approval at the upcoming Annual General Meeting (AGM). The company also approved its audited financial results for Q4 and FY26, which showed that its six subsidiaries contributed a combined annual revenue of ₹40.55 Cr. However, these subsidiaries reported a consolidated net loss of ₹8.49 Cr for the full year, which investors should monitor alongside the parent company's performance.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹0.75 per equity share (75% of face value ₹1).Audited annual results for FY26 approved by the Board on May 26, 2026.Six subsidiaries reported total annual revenue of ₹40.55 Cr and a net loss of ₹8.49 Cr.Total assets of audited subsidiaries stood at ₹163.95 Cr as of March 31, 2026.Dividend to be credited within 30 days of shareholder approval at the AGM.
👀 கவனிக்க வேண்டியவை
Investors should consider the dividend yield based on the current market price and review the full earnings report to assess the impact of subsidiary losses on overall group profitability. The stock remains a relevant play in the hospitality sector with a focus on upcoming AGM dates for dividend entitlement.
Sai Parenterals FY26 Consolidated Revenue Hits ₹381 Cr; Standalone PAT Jumps 64% YoY
Sai Parenterals reported a strong performance for FY26, with consolidated revenue reaching ₹381 crore, significantly aided by the acquisition of Australia-based Noumed Pharmaceuticals. On a standalone basis, the company saw a robust 64% YoY growth in PAT to ₹17 crore, driven by a massive 250% surge in CDMO revenue. The company successfully listed in April 2026 after a ₹285 crore IPO, utilizing funds for capacity expansion and R&D. With 67 dossiers currently under development and a new facility in Adelaide on track for Q4FY27, the company is aggressively targeting regulated markets.
முக்கிய அம்சங்கள்
Consolidated FY26 revenue reached ₹381 crore, with Q4FY26 contributing ₹198 crore following the Noumed consolidation.Standalone PAT grew 64% YoY to ₹17 crore, while standalone EBITDA increased 23% to ₹33 crore.CDMO revenue surged by over 250% YoY, reflecting deeper engagement with global customers and long-term contracts.Expanded portfolio by 93 dossiers in FY26, with 67 additional dossiers currently under development for export-led growth.Investing ₹111 crore in Unit III expansion and AUD 53 million for a new TGA-approved facility in Australia.
👀 கவனிக்க வேண்டியவை
Investors should focus on the successful integration of Noumed and the ramp-up of the CDMO business which is driving higher margins. The progress of the Adelaide facility and EU-GMP upgradations of Indian units are key catalysts for future valuation re-rating.
EID Parry Standalone Q4 FY26 Net Loss at ₹340 Cr due to ₹477 Cr Exceptional Item
EID Parry reported a standalone total income of ₹1,017 crore for the quarter ended March 31, 2026. The company recorded a significant standalone net loss of ₹340 crore, which was primarily driven by a substantial exceptional item loss of ₹477.5 crore. Despite the bottom-line loss, the company maintained an operational profit before tax and exceptional items of ₹178.2 crore. The statutory auditors have issued an unmodified opinion on these financial results.
முக்கிய அம்சங்கள்
Standalone Revenue from operations for the quarter stood at ₹845.5 crore.Reported a standalone net loss of ₹340.4 crore for Q4 FY26.A massive exceptional item charge of ₹477.5 crore significantly impacted the quarterly performance.Profit before tax and exceptional items was positive at ₹178.2 crore.The 51st Annual General Meeting is scheduled for August 12, 2026.
👀 கவனிக்க வேண்டியவை
Investors should scrutinize the nature of the ₹477.5 crore exceptional item to understand if it represents a one-time write-off or a structural issue. While the headline loss is concerning, the positive operational profit before exceptional items suggests the core business remains viable.
Park Medi World to Acquire The Medicity Hospital for ₹177 Crore
Park Medi World Limited has approved the 100% acquisition of V3 Healthcare Private Limited, which operates the 330-bed 'The Medicity Hospital' in Rudrapur, Uttarakhand. The all-cash deal is valued at approximately ₹177 crore and marks the company's entry into its sixth state. The acquisition will be executed in two tranches, with 80% ownership expected by August 2026 and the remaining 20% by April 2030. The target entity reported a turnover of ₹55.74 crore in FY26, representing a steady growth from ₹42.46 crore in FY24.
முக்கிய அம்சங்கள்
Acquisition of 100% stake in V3 Healthcare Private Limited for an estimated ₹177 crore in cash.The Medicity Hospital is a 330-bed multi-super speciality facility, the largest in the Kumaon region.Target turnover has grown consistently from ₹42.46 crore in FY24 to ₹55.74 crore in FY26.Transaction structure involves 80% stake acquisition by August 31, 2026, and 20% by April 30, 2030.Expansion supports Park Group's long-term goal of reaching a total capacity of 5,790 beds by March 2028.
👀 கவனிக்க வேண்டியவை
Investors should view this as a strategic expansion that strengthens the company's North India footprint and adds immediate scale. Monitor the post-acquisition integration and its impact on the company's consolidated EBITDA margins.
Sai Parenterals Q4 PAT Surges 736% to ₹13.25 Cr; FY27 Revenue Target Set at ₹750 Cr
Sai Parenterals reported an exceptional Q4 FY26 with PAT surging 736% YoY to ₹13.25 crore, driven by the successful integration of Noumed (Australia) and a 250% jump in CDMO revenues. Full-year FY26 revenue grew 140% to ₹380.99 crore, reflecting the impact of strategic acquisitions and export growth. The company successfully completed its IPO in March 2026, raising ₹285 crore to fund a massive ₹440 crore capex program. Management has issued aggressive guidance for FY27, targeting ₹750 crore in revenue and an improved EBITDA margin of 17%.
முக்கிய அம்சங்கள்
Q4 FY26 revenue grew 166.65% YoY to ₹197.93 Cr, while PAT increased 736.04% to ₹13.25 Cr.FY26 consolidated revenue reached ₹380.99 Cr (+140.37% YoY) following the acquisition of Noumed Australia.Management targets FY27 revenue of ₹750 Cr and EBITDA margins of 17%, nearly doubling current revenue levels.Ongoing capex of ₹440 Cr includes a new R&D center in India and Australia's largest modern pharmaceutical plant.CDMO revenues surged by over 250% YoY, supported by 88 new product dossiers added in FY26 and 67 more in the pipeline.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's ability to execute its ₹440 crore capex and achieve the ambitious ₹750 crore revenue target for FY27. The stock remains a high-growth play in the CDMO and injectable space following its recent listing and successful Australian integration.
Paramount Communications FY26 Revenue Up 23% to ₹19,122 Mn; Q4 PAT Recovers by 9.5%
Paramount Communications reported a 22.8% YoY growth in FY26 revenue to ₹19,122 Mn, though full-year PAT declined 30.5% to ₹602 Mn due to US tariff disruptions. However, Q4 FY26 showed a strong recovery with PAT rising 9.5% YoY to ₹205 Mn as the company successfully pivoted to the domestic market. The domestic order book grew significantly by 55% YoY to ₹5,078 Mn, helping offset a 77% decline in export orders. The company is also progressing with a ₹300 Cr Greenfield expansion in Madhya Pradesh to enter the high-margin EHV cable segment by FY28.
முக்கிய அம்சங்கள்
FY26 Revenue grew 22.8% YoY to ₹19,122 Mn, while full-year EBITDA margin compressed to 6.0% from 8.5%.Q4 FY26 EBITDA margin recovered to 6.7% from 4.3% in Q3 FY26, signaling a turnaround from export tariff impacts.Domestic order book reached a record ₹5,078 Mn (+55% YoY), driven by a 66% surge in power cable demand.Greenfield project in Narmadapuram involves ₹300 Cr investment for EHV cables with partial commissioning in Q1 FY28.Metal throughput increased 12% YoY to 29,664 MTPA, maintaining a strong 3-year CAGR of approximately 45%.
👀 கவனிக்க வேண்டியவை
Investors should monitor the stabilization of export margins and the execution timeline of the Narmadapuram EHV project. While domestic growth is robust, the company's ability to navigate global trade volatility remains a key factor for long-term profitability.
Sai Parenterals Reports Zero Deviation in Utilization of ₹2,850 Million IPO Proceeds
Sai Parenterals Limited has submitted its statement of deviation for the quarter and year ended March 31, 2026, confirming that IPO funds are being handled as per the offer document. The company raised ₹2,850 million through its Initial Public Offer in late March 2026. As of the reporting date, no funds have been diverted from their original objects, which include significant allocations for capacity expansion and debt repayment. The monitoring agency, India Ratings & Research, and the company's Audit Committee have reviewed and confirmed the status.
முக்கிய அம்சங்கள்
Successfully raised ₹2,850 million through an IPO conducted between March 24 and March 27, 2026.Confirmed zero deviation or variation in the utilization of proceeds for the period ending March 31, 2026.Major allocations include ₹1,107.95 million for capacity expansion and ₹356.41 million for loan repayments related to the acquisition of Noumed Pharmaceuticals (Australia).Allocated ₹180.23 million for the establishment of a new R&D Centre and ₹330 million for working capital requirements.India Ratings & Research Private Limited is acting as the monitoring agency for the fund utilization.
👀 கவனிக்க வேண்டியவை
Investors should track subsequent quarterly filings to ensure the ₹2,850 million is deployed timely into the high-growth capacity expansion and R&D projects as promised.
Sai Parenterals Reports Q3 FY26 Consolidated PAT of ₹33.37 Million Post-IPO
Sai Parenterals Limited has released its first set of financial results post-listing for the quarter and nine months ended December 31, 2025. On a consolidated basis, the company reported a revenue of ₹892.11 million for the quarter, though it faced a loss before tax of ₹16.25 million, which turned into a PAT of ₹33.37 million due to deferred tax credits. The standalone performance remained profitable with a nine-month PAT of ₹68.28 million. A significant development is the completed acquisition of a 74.64% stake in UK-based Noumed Life Sciences for AUD 22 million, which is now reflected in the consolidated figures.
முக்கிய அம்சங்கள்
Consolidated Revenue from Operations for Q3 FY26 stood at ₹892.11 million.Consolidated Profit After Tax (PAT) for the quarter was ₹33.37 million, supported by a ₹55.57 million deferred tax credit.Standalone Nine-Month revenue reached ₹1,054.59 million with a PAT of ₹68.28 million.Completed acquisition of 74.64% stake in Noumed Life Sciences Limited (UK) for an aggregate consideration of AUD 22 million.The company reported an unmodified audit opinion for the financial year ended March 31, 2026.
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the operational integration of the UK-based Noumed Life Sciences, as the consolidated entity is currently reporting losses at the pre-tax level despite high revenue scaling. The stock's performance will likely depend on the company's ability to turn the consolidated operations profitable without relying on tax adjustments.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
